Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TP-102 (TechnoPhage)
- Development stage
- Unknown
- Lead developer
- TechnoPhage
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation
01
Overview
TP-102 is a therapeutic bacteriophage cocktail developed by Technophage for the treatment of severe respiratory infections, specifically ventilator-associated pneumonia (VAP). The cocktail is composed of five distinct lytic bacteriophages, including members of the *Myoviridae* family, that specifically target and eliminate *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. By utilizing a cocktail of multiple phages, TP-102 provides broad coverage against various clinical isolates of these Gram-negative pathogens and minimizes the risk of bacterial resistance. The drug is designed for administration via inhalation using a nebulizer, allowing for direct delivery to the infected lung tissue. TP-102 has been evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and efficacy in patients colonized or infected with these multidrug-resistant bacteria in intensive care settings.
- Other names
- Technophage VAP cocktailBacteriophage cocktail TP-102myoviridae bacteriophage against pseudomonas aeruginosa
02
Targets
SpA (Staphylococcal protein A)
Beyond the preview
Go deeper on TP-102 (TechnoPhage).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TP-102 (TechnoPhage).